caldaret

11/01/2006 - "This first human experience with caldaret prior to direct PCI for large STEMI shows a good safety profile. "
11/01/2006 - "STEMI patients (n=387) with > or =10 mm summed ST-deviation on electrocardiogram were randomized to receive a 48 h infusion of caldaret 57.5 mg [lower dose (LD)], caldaret 172.5 mg [higher dose (HD)], or placebo, starting before PCI. "
11/01/2006 - "To examine the safety and efficacy of intravenous caldaret in patients with large acute ST-elevation myocardial infarction (STEMI) undergoing percutaneous coronary intervention (PCI). "
11/01/2006 - "Results of the first clinical study of adjunctive CAldaret (MCC-135) in patients undergoing primary percutaneous coronary intervention for ST-Elevation Myocardial Infarction: the randomized multicentre CASTEMI study."
01/01/2009 - "In conclusion, treatment with intravenous caldaret in patients with STEMI undergoing primary PCI is associated with a significant decrease in the incidence of severe LV dysfunction."

02/01/2007 - "Intravenously infused caldaret (3 or 30 microg/kg per hour) for 30 min at LCX-reperfusion markedly reduced infarct size (by 51.3% or 71.9%, respectively). "
02/01/2007 - "Caldaret, an intracellular Ca2+ handling modulator, limits infarct size of reperfused canine heart."
01/01/2009 - "At day 30 after the infarct, there was a significant decrease in the incidence of LV dysfunction in patients receiving low and high doses of caldaret versus placebo (8.0%, 6.9% vs 17.5%, p <0.05 for the 2 comparisons). "
02/01/2007 - "Diltiazem (2000 microg/kg per hour) also reduced infarct size (by 36.1%), but unlike caldaret, was accompanied by the significant increase in Endo/Epi ratio in the ischemic region and decrease in double-product. "
01/01/2008 - "The objective of the study was to test the hypothesis that intracellular calcium modulation by 5-methyl-2-[piperazin-1-yl] benzene sulfonic acid monohydrate (MCC-135 [Caldaret]; Mitsubishi Pharma Corporation, Osaka, Japan) would preserve left ventricular function and reduce infarct size in patients undergoing primary percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI). "

01/01/2009 - "The incidence of LV dysfunction in patients receiving low- and high-dose caldaret was compared with placebo. "
01/01/2009 - "In conclusion, treatment with intravenous caldaret in patients with STEMI undergoing primary PCI is associated with a significant decrease in the incidence of severe LV dysfunction."
01/01/2009 - "At day 30 after the infarct, there was a significant decrease in the incidence of LV dysfunction in patients receiving low and high doses of caldaret versus placebo (8.0%, 6.9% vs 17.5%, p <0.05 for the 2 comparisons). "
01/01/2009 - "The aim of this subanalysis was to examine whether caldaret decreases the incidence of LV dysfunction (LV ejection fraction <or=30%) in patients with STEMI undergoing primary PCI. "
01/01/2009 - "Effect of caldaret on the incidence of severe left ventricular dysfunction in patients with ST-elevation myocardial infarction undergoing primary coronary intervention."

02/01/2007 - "These results suggest that the amelioration of intracellular Ca(2+) handling dysfunction achieved by caldaret leads to cardioprotective effects against reperfusion injury following prolonged ischemia."
02/01/2007 - "The cardioprotective effect of caldaret, a novel intracellular Ca(2+) handling modulator that acts through reverse-mode Na(+)/Ca(2+) exchanger inhibition and potential sarcoplasmic reticulum (SR) Ca(2+) uptake enhancement, against reperfusion injury was investigated. "

02/01/2007 - "These results suggest that the amelioration of intracellular Ca(2+) handling dysfunction achieved by caldaret leads to cardioprotective effects against reperfusion injury following prolonged ischemia."